New Search

If you are not happy with the results below please do another search

Search
Generic filters

50 search results for:

11

Two FDA Wins in Two Days for Incyte

Incyte announced Sept. 22 that the Food and Drug Administration approved the company’s Jakafi (ruxolitinib) to treat chronic graft-versus-host disease, one day after the U.S. regulator gave the green light to the cream Opzelura (ruxolinitib) for the short-term and non-continuous chronic treatment of mild-to-moderate atopic dermatitis.

17

Severe COVID-19 may trigger autoimmune conditions; New variants cause more virus in the air

Severe Covid-19 may trick the immune system into producing so-called autoantibodies that have the potential to eventually attack healthy tissue and cause inflammatory diseases, researchers warned in a paper published in Nature Communications. Another study suggests that the virus that causes Covid-19 may be getting better at traveling into the air

18

Llama Nanobodies May be Missing Link in COVID-19 Therapeutics

Monoclonal antibodies are playing a key therapeutic role in the treatment of some Covid-19 patients, but new research suggests that nanobodies derived from llamas could provide an alternative to monoclonal antibodies through a more effective delivery method—inhalation.

20

National Survey: “Trust” at the Heart of Low U.S. Vaccination Rates

Why aren’t more people getting vaccinated? The answer comes down to a lack of trust, according to the COVID States Project, the largest ongoing national survey tracking people’s opinions and behaviors during the pandemic.